Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disorder characterised by left ventricular hypertrophy. A subgroup of patients develops limiting symptoms in association with left ventricular outflow tract obstruction (LVOTO). Current international guidelines recommend that symptomatic patients are initially treated by alleviating exacerbating factors and negatively inotropic medication. Drug-refractory symptoms require a comprehensive evaluation of the mechanism of LVOTO and review by a multidisciplinary team to consider the relative merits of myectomy, alcohol septal ablation (ASA) and pacing. This article provides a brief overview of HCM and the pathophysiology of LVOTO, and reviews the use of ASA in patients with drug-refractory symptoms secondary to LVOTO.
Saidi Mohiddin - The Heart Muscle Disease Clinic, London Chest Hospital, London, UK
Charles Knight - The Heart Muscle Disease Clinic, London Chest Hospital, London, UK
Constantinos O’Mahony - The Heart Muscle Disease Clinic, London Chest Hospital, London, UK